Maribavir does not significantly influence tacrolimus dose requirements in solid organ transplant recipients

Transpl Infect Dis. 2022 Aug;24(4):e13869. doi: 10.1111/tid.13869. Epub 2022 Jun 1.
No abstract available

Keywords: cytomegalovirus; drug-drug interaction; maribavir.

Publication types

  • Letter

MeSH terms

  • Benzimidazoles
  • Dichlororibofuranosylbenzimidazole / analogs & derivatives
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Organ Transplantation* / adverse effects
  • Ribonucleosides*
  • Tacrolimus / therapeutic use
  • Transplant Recipients

Substances

  • Benzimidazoles
  • Immunosuppressive Agents
  • Ribonucleosides
  • Dichlororibofuranosylbenzimidazole
  • maribavir
  • Tacrolimus